SynthesisBMC cardiovascular disorders2025
Efficacy and safety of adenosine for supraventricular tachycardia: A meta-analysis utilizing BioMedGPT-LM-7B.
Synthesis in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Effectiveness of the modified Valsalva maneuver vs the standard Valsalva maneuver for the conversion of supraventricular tachycardia to normal sinus rhythm in the emergency department: a systematic review and meta analysis.Internal and emergency medicine · 2026Review
- Intracardiac adenosine triphosphate for cardioversion of supraventricular tachycardia in a hydropic foetus: a case report.European heart journal. Case reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with supraventricular tachycardia (SVT) often experience multiple clinical symptoms that require emergency treatment. This study utilized BioMedGPT-LM-7B, an artificial intelligence (AI) model, to comprehensively evaluate the efficacy and adverse effects of adenosine/adenosine triphosphate (ATP) versus calcium channel blockers (CCBs) in SVT treatment.
methodsThis study conducted a comprehensive search of multiple medical databases, as well as major trial registries up to December 2024. We performed dual screening and assessment using BioMedGPT-LM-7B and the traditional Cochrane bias risk tool. The primary outcomes were the rate of sinus rhythm restoration and major adverse events, while secondary outcomes included time to restoration, relapse to SVT post-reversion, and any minor adverse events. Outcome measurements were based on odds ratios (OR) and Mean Difference (MD), with the quality of primary outcomes assessed using the GRADE method.
resultsThis study included 10 RCTs with a total of 960 SVT patients admitted to the emergency department. Comparing BioMedGPT-LM-7B with the traditional Cochrane bias risk tool, we found no significant differences in random sequence generation and selective reporting. Moderate evidence showed no difference between adenosine/ATP and CCBs in restoring sinus rhythm (OR = 1.44, 95% CI [0.89,2.34]), but adenosine/ATP had a shorter time to reversion (MD = 423,24, 95% CI [293.54, 552.93]). However, the research findings show a lower level of evidence regarding differences in side effects among the drugs mentioned above. Three cases of hypotension were reported in the CCB group, whereas none were reported in the adenosine group.
conclusionAdenosine/ATP and CCBs have similar efficacy in treating SVT, but adenosine/ATP has a shorter conversion time and no reported cases of hypotension. Clinical studies indicate that adenosine has a higher success rate and faster conversion time in restoring sinus rhythm compared to ATP, with milder side effects. However, further prospective studies are needed to evaluate patient experience and potential adverse events, ensuring a more comprehensive understanding of treatment safety and efficacy. Additionally, this study showcases BioMedGPT-LM-7B's potential for medical data analysis and future meta-analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.